Blog
Health Canada Compliance Insights
NHPD testing guides, Canadian regulatory updates, and compliance insights for natural health product manufacturers, supplement brands, and Amazon Canada sellers.
Quality Technical Agreements for Canadian CMOs: What Health Canada GMP Actually Requires
A practical breakdown of what Health Canada GMP (GUI-0001, C.02.012) requires in a Quality Technical Agreement between pharmaceutical manufacturers and Canadian CMOs.
Adverse Drug Reaction Reporting in Canada: What Health Canada Actually Requires from Drug Sponsors
A practical breakdown of Health Canada's ADR reporting requirements under C.01.017 — timelines, submission formats, and what Canadian MAHs most often get wrong.
Certificate of Analysis Verification for Imported APIs in Canada: What Health Canada's GMP Requirements Actually Demand
Health Canada GMP requires more than spec-checking for imported API COAs. Learn what your verification files must contain and where manufacturers get cited.
Health Canada's Special Access Program: What Drug Sponsors and Manufacturers Actually Need to Know
Health Canada's Special Access Program places real obligations on manufacturers, not just practitioners. Here's what drug sponsors and CROs need in place.
Supplemented Food or NHP? How Canada's Natural Health Products Regulations Draw the Line
Learn how Health Canada's natural health products regulations distinguish NHPs from supplemented foods — and why getting it wrong can trigger a recall.
Analytical Method Transfer to a Contract Laboratory Under Canada GMP: What Health Canada Inspectors Expect
Analytical method transfer to a contract lab under Canada GMP requires more than a comparison study. Here's what Health Canada inspectors actually look for in your AMT documentation.
Why NPN Applications Fail: NHPD Submission Mistakes Under Canada's Natural Health Products Regulations
Most NPN applications stall not from bad formulations but from avoidable evidence and GMP errors. Here's what Health Canada reviewers actually look for.
Stability Study Design for Canadian Drug Submissions Under ICH Q1A
How to design a stability study that meets Health Canada's ICH Q1A requirements — batch minimums, storage conditions, filing timelines, and post-approval commitments.
Health Canada's Post-Market Surveillance Requirements for NHPs: What Most Licence Holders Are Missing
NHP product licences are just the beginning. Health Canada's ongoing post-market obligations under SOR/2003-196 are often the weakest link in Canadian compliance programs.
ISO 17025 Accreditation in Canada: What Canada GMP Compliance Requires From Your Contract Testing Lab
ISO 17025 accreditation confirms a lab has a quality system — not that your specific methods are in scope. Here's what Canada GMP actually demands from your contract lab.
Canada GMP Requirements for a Drug Establishment Licence: What Health Canada Actually Expects
A practical guide to Health Canada GMP requirements for Drug Establishment Licence applicants — covering C.02, GUI-0001, inspection priorities, and pre-inspection readiness steps.
Aseptic Processing Under Health Canada GMP: What Sterile Drug Manufacturers Actually Need to Satisfy Inspectors
Canada GMP sterile manufacturing requires more than cleanroom certification. Here's what Health Canada GMP inspectors actually scrutinize in aseptic processing.
Temperature Mapping and Cold Chain Validation Under Canada GMP: What Health Canada Inspectors Actually Find
Temperature control deficiencies rank among the most cited Canada GMP inspection findings. Here's how to build a defensible cold chain validation program.
What Health Canada Actually Expects From Your Pharmacovigilance System — And Where Most MAHs Fall Short
Health Canada's post-market drug safety reporting for Canadian MAHs: expedited ADR submissions, PSURs under ICH E2C(R2), and what inspectors actually check.
Out-of-Specification Investigations Under Health Canada GMP: What Your Lab Procedure Must Include
What Health Canada GMP guidelines require for out-of-specification investigations: the two-phase process, required SOP elements, and common inspection findings.
Nitrosamine Impurities in Canadian Drug Products: What Health Canada's Guidance Actually Requires
Health Canada requires a structured three-step nitrosamine risk assessment for every Canadian drug product. Here's what compliant GMP programs actually look like.
Health Canada's GMP Mutual Recognition Agreements: When Foreign Inspection Acceptance Actually Works
Health Canada accepts GMP inspection results from select partner authorities — but with conditions most manufacturers miss. Here's what actually applies.
Bioequivalence Study Design for Health Canada Drug Applications: What Generic Drug Sponsors Need to Know
Health Canada bioequivalence study design for ANDS filings: protocol requirements, statistical thresholds, and CRO guidance for generic drug sponsors.